Khalid Sawalha
Concepts (213)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mitral Valve Insufficiency | 3 | 2021 | 56 | 1.940 |
Why?
| | Heart Valve Prosthesis Implantation | 3 | 2021 | 103 | 1.800 |
Why?
| | Ventricular Fibrillation | 2 | 2025 | 18 | 1.760 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2025 | 27 | 1.090 |
Why?
| | Coronary Artery Disease | 4 | 2025 | 323 | 1.070 |
Why?
| | Echocardiography, Doppler | 2 | 2025 | 56 | 1.060 |
Why?
| | Metformin | 2 | 2025 | 82 | 1.010 |
Why?
| | Hematoma | 3 | 2022 | 67 | 1.000 |
Why?
| | Hypoglycemic Agents | 4 | 2025 | 223 | 1.000 |
Why?
| | Tachycardia, Ventricular | 1 | 2025 | 45 | 0.930 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2025 | 79 | 0.930 |
Why?
| | Heart Failure | 4 | 2023 | 527 | 0.930 |
Why?
| | Ventricular Function, Right | 1 | 2025 | 40 | 0.910 |
Why?
| | Heart Rate | 1 | 2025 | 311 | 0.860 |
Why?
| | Catheter Ablation | 1 | 2025 | 125 | 0.850 |
Why?
| | Pulmonary Artery | 1 | 2025 | 142 | 0.840 |
Why?
| | Cerebral Hemorrhage | 2 | 2022 | 102 | 0.830 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2025 | 570 | 0.810 |
Why?
| | Heart Ventricles | 1 | 2025 | 259 | 0.800 |
Why?
| | Humans | 47 | 2025 | 52441 | 0.790 |
Why?
| | Cues | 1 | 2023 | 53 | 0.780 |
Why?
| | Arthritis, Rheumatoid | 2 | 2022 | 114 | 0.770 |
Why?
| | Echocardiography | 1 | 2025 | 409 | 0.750 |
Why?
| | Stroke | 3 | 2020 | 527 | 0.680 |
Why?
| | Liver Diseases | 1 | 2021 | 81 | 0.670 |
Why?
| | Vocal Cord Paralysis | 1 | 2020 | 23 | 0.670 |
Why?
| | Hypothermia | 1 | 2021 | 38 | 0.670 |
Why?
| | Atherosclerosis | 1 | 2023 | 224 | 0.660 |
Why?
| | Cryoglobulins | 1 | 2020 | 6 | 0.640 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2020 | 8 | 0.640 |
Why?
| | Niacin | 1 | 2020 | 6 | 0.640 |
Why?
| | Cholecystitis | 1 | 2020 | 11 | 0.640 |
Why?
| | Optic Neuritis | 1 | 2020 | 19 | 0.630 |
Why?
| | Vasculitis | 1 | 2020 | 28 | 0.630 |
Why?
| | Hypertriglyceridemia | 1 | 2020 | 19 | 0.630 |
Why?
| | Myocarditis | 1 | 2020 | 49 | 0.630 |
Why?
| | Aneurysm, False | 1 | 2020 | 42 | 0.610 |
Why?
| | Aged | 18 | 2025 | 10242 | 0.610 |
Why?
| | Brain Ischemia | 1 | 2020 | 168 | 0.600 |
Why?
| | Pancreatitis | 1 | 2020 | 66 | 0.600 |
Why?
| | Motor Neuron Disease | 1 | 2019 | 6 | 0.600 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 230 | 0.590 |
Why?
| | Respiratory Insufficiency | 1 | 2020 | 114 | 0.580 |
Why?
| | Insulin | 2 | 2023 | 485 | 0.570 |
Why?
| | Neuroimaging | 1 | 2019 | 91 | 0.560 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2020 | 198 | 0.530 |
Why?
| | Cardiovascular Diseases | 4 | 2023 | 493 | 0.490 |
Why?
| | Treatment Outcome | 10 | 2025 | 5508 | 0.490 |
Why?
| | Male | 20 | 2025 | 26874 | 0.480 |
Why?
| | Cerebral Angiography | 3 | 2022 | 90 | 0.470 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 1507 | 0.460 |
Why?
| | Brain | 3 | 2020 | 1337 | 0.440 |
Why?
| | Stroke Volume | 3 | 2025 | 148 | 0.410 |
Why?
| | Female | 21 | 2025 | 28277 | 0.410 |
Why?
| | Myocardial Infarction | 4 | 2024 | 449 | 0.410 |
Why?
| | Hospital Mortality | 4 | 2025 | 451 | 0.410 |
Why?
| | Coronary Angiography | 3 | 2024 | 367 | 0.410 |
Why?
| | Middle Aged | 13 | 2025 | 13133 | 0.400 |
Why?
| | Rheumatic Diseases | 2 | 2022 | 17 | 0.360 |
Why?
| | Risk Factors | 7 | 2025 | 3971 | 0.340 |
Why?
| | Autoimmune Diseases | 2 | 2022 | 87 | 0.340 |
Why?
| | Aged, 80 and over | 8 | 2021 | 3449 | 0.330 |
Why?
| | Mitral Valve | 2 | 2021 | 57 | 0.330 |
Why?
| | Hospitals | 2 | 2021 | 182 | 0.310 |
Why?
| | Cardiac Catheterization | 2 | 2021 | 228 | 0.290 |
Why?
| | Hospitalization | 3 | 2021 | 731 | 0.280 |
Why?
| | Patient Readmission | 2 | 2020 | 249 | 0.280 |
Why?
| | Blood Flow Velocity | 2 | 2025 | 97 | 0.270 |
Why?
| | Retrospective Studies | 8 | 2022 | 6694 | 0.250 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 938 | 0.250 |
Why?
| | Adult | 8 | 2025 | 14205 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 1140 | 0.240 |
Why?
| | Origanum | 1 | 2025 | 2 | 0.240 |
Why?
| | Action Potentials | 1 | 2025 | 128 | 0.230 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2025 | 71 | 0.230 |
Why?
| | Risk Assessment | 3 | 2025 | 1349 | 0.230 |
Why?
| | Electrocardiography | 2 | 2024 | 273 | 0.220 |
Why?
| | Acute Disease | 3 | 2020 | 384 | 0.220 |
Why?
| | Phenols | 1 | 2025 | 96 | 0.220 |
Why?
| | Antiviral Agents | 1 | 2025 | 173 | 0.210 |
Why?
| | Recurrence | 1 | 2025 | 680 | 0.210 |
Why?
| | Antioxidants | 1 | 2025 | 255 | 0.210 |
Why?
| | Time Factors | 3 | 2025 | 2987 | 0.200 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2023 | 3 | 0.200 |
Why?
| | Plant Extracts | 1 | 2025 | 199 | 0.200 |
Why?
| | Angina Pectoris, Variant | 1 | 2023 | 4 | 0.200 |
Why?
| | Patient Discharge | 2 | 2022 | 320 | 0.200 |
Why?
| | Coronary Vasospasm | 1 | 2023 | 5 | 0.200 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 871 | 0.200 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 55 | 0.200 |
Why?
| | Cardiovascular System | 1 | 2023 | 55 | 0.190 |
Why?
| | Ventricular Function, Left | 2 | 2023 | 174 | 0.190 |
Why?
| | Exercise Test | 1 | 2023 | 134 | 0.190 |
Why?
| | Arrhythmias, Cardiac | 1 | 2023 | 97 | 0.190 |
Why?
| | Coronary Occlusion | 1 | 2023 | 80 | 0.190 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2023 | 107 | 0.190 |
Why?
| | Reproducibility of Results | 1 | 2025 | 1223 | 0.180 |
Why?
| | Cardiology | 1 | 2023 | 105 | 0.180 |
Why?
| | Coronary-Subclavian Steal Syndrome | 1 | 2021 | 2 | 0.180 |
Why?
| | Subclavian Steal Syndrome | 1 | 2021 | 5 | 0.180 |
Why?
| | Mammary Arteries | 1 | 2021 | 10 | 0.170 |
Why?
| | Insulin Resistance | 1 | 2023 | 281 | 0.170 |
Why?
| | Frail Elderly | 1 | 2021 | 35 | 0.170 |
Why?
| | Troponin | 1 | 2021 | 16 | 0.170 |
Why?
| | Creatine Kinase, MB Form | 1 | 2021 | 10 | 0.170 |
Why?
| | Binge Drinking | 1 | 2021 | 25 | 0.170 |
Why?
| | Biliary Tract Diseases | 1 | 2021 | 14 | 0.170 |
Why?
| | Creatine Kinase | 1 | 2021 | 31 | 0.170 |
Why?
| | Lorazepam | 1 | 2020 | 13 | 0.170 |
Why?
| | Cardiac Tamponade | 1 | 2021 | 27 | 0.170 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2020 | 23 | 0.170 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2020 | 34 | 0.160 |
Why?
| | Prognosis | 2 | 2023 | 2100 | 0.160 |
Why?
| | Status Epilepticus | 1 | 2020 | 34 | 0.160 |
Why?
| | Disability Evaluation | 1 | 2020 | 92 | 0.160 |
Why?
| | Mastocytosis, Systemic | 1 | 2020 | 6 | 0.160 |
Why?
| | Hospitals, Community | 1 | 2020 | 19 | 0.160 |
Why?
| | Hepatic Artery | 1 | 2020 | 21 | 0.160 |
Why?
| | Magnesium | 1 | 2020 | 35 | 0.160 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 81 | 0.160 |
Why?
| | Optic Disk | 1 | 2020 | 20 | 0.160 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2020 | 46 | 0.160 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 816 | 0.160 |
Why?
| | Hospitals, Rural | 1 | 2020 | 28 | 0.160 |
Why?
| | Exanthema | 1 | 2020 | 33 | 0.150 |
Why?
| | Severity of Illness Index | 2 | 2020 | 1045 | 0.150 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2020 | 91 | 0.150 |
Why?
| | Cerebrovascular Circulation | 1 | 2020 | 126 | 0.150 |
Why?
| | Iohexol | 1 | 2019 | 4 | 0.150 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 212 | 0.150 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 318 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2020 | 136 | 0.150 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2023 | 328 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2020 | 93 | 0.150 |
Why?
| | Intracranial Hemorrhages | 1 | 2019 | 43 | 0.150 |
Why?
| | Seizures | 1 | 2020 | 201 | 0.150 |
Why?
| | Aortic Valve Stenosis | 1 | 2020 | 79 | 0.150 |
Why?
| | Alcoholism | 1 | 2021 | 236 | 0.140 |
Why?
| | Glucocorticoids | 1 | 2020 | 234 | 0.140 |
Why?
| | Acute Coronary Syndrome | 1 | 2020 | 106 | 0.140 |
Why?
| | Aortic Valve | 1 | 2020 | 130 | 0.140 |
Why?
| | Heart Diseases | 1 | 2021 | 217 | 0.140 |
Why?
| | Hypertension | 1 | 2023 | 560 | 0.140 |
Why?
| | Hemorrhage | 1 | 2020 | 225 | 0.140 |
Why?
| | Liver Cirrhosis | 1 | 2020 | 243 | 0.140 |
Why?
| | Cardiac Surgical Procedures | 1 | 2021 | 329 | 0.140 |
Why?
| | Body Mass Index | 1 | 2021 | 701 | 0.140 |
Why?
| | Contrast Media | 1 | 2019 | 173 | 0.140 |
Why?
| | Respiration, Artificial | 1 | 2020 | 288 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1028 | 0.120 |
Why?
| | Disease Progression | 1 | 2019 | 870 | 0.120 |
Why?
| | Heart | 3 | 2023 | 352 | 0.120 |
Why?
| | Young Adult | 2 | 2020 | 4346 | 0.100 |
Why?
| | Registries | 3 | 2023 | 638 | 0.100 |
Why?
| | Shock, Cardiogenic | 2 | 2022 | 35 | 0.090 |
Why?
| | Animals | 1 | 2025 | 13485 | 0.080 |
Why?
| | Health Status | 2 | 2022 | 300 | 0.080 |
Why?
| | Comorbidity | 2 | 2020 | 637 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 1677 | 0.060 |
Why?
| | Cohort Studies | 2 | 2021 | 1576 | 0.060 |
Why?
| | Prospective Studies | 2 | 2022 | 2433 | 0.060 |
Why?
| | MCF-7 Cells | 1 | 2025 | 63 | 0.060 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2025 | 69 | 0.060 |
Why?
| | Molecular Docking Simulation | 1 | 2025 | 93 | 0.060 |
Why?
| | HeLa Cells | 1 | 2025 | 243 | 0.060 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2025 | 249 | 0.060 |
Why?
| | Metabolome | 1 | 2025 | 100 | 0.060 |
Why?
| | Metabolomics | 1 | 2025 | 147 | 0.050 |
Why?
| | Telemetry | 1 | 2023 | 27 | 0.050 |
Why?
| | Sodium | 1 | 2023 | 92 | 0.050 |
Why?
| | Chest Pain | 1 | 2023 | 55 | 0.050 |
Why?
| | Syncope | 1 | 2023 | 31 | 0.050 |
Why?
| | Habits | 1 | 2022 | 20 | 0.050 |
Why?
| | Inflammasomes | 1 | 2023 | 64 | 0.050 |
Why?
| | Outpatients | 1 | 2023 | 128 | 0.050 |
Why?
| | Alcohol-Related Disorders | 1 | 2021 | 43 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2021 | 16 | 0.040 |
Why?
| | Iatrogenic Disease | 1 | 2021 | 25 | 0.040 |
Why?
| | Diazepam | 1 | 2020 | 18 | 0.040 |
Why?
| | Chronic Disease | 1 | 2023 | 579 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 356 | 0.040 |
Why?
| | Reperfusion | 1 | 2020 | 12 | 0.040 |
Why?
| | Nurses | 1 | 2021 | 54 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2022 | 235 | 0.040 |
Why?
| | Heart Atria | 1 | 2021 | 62 | 0.040 |
Why?
| | Dyspnea | 1 | 2021 | 78 | 0.040 |
Why?
| | Thromboembolism | 1 | 2021 | 48 | 0.040 |
Why?
| | Counseling | 1 | 2021 | 133 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2020 | 71 | 0.040 |
Why?
| | Patient Admission | 1 | 2020 | 80 | 0.040 |
Why?
| | United States | 2 | 2021 | 5215 | 0.040 |
Why?
| | Coronary Artery Bypass | 1 | 2021 | 135 | 0.040 |
Why?
| | Recovery of Function | 1 | 2020 | 201 | 0.040 |
Why?
| | Hemodynamics | 1 | 2020 | 235 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 73 | 0.040 |
Why?
| | Insurance, Health | 1 | 2020 | 132 | 0.040 |
Why?
| | Health Care Costs | 1 | 2020 | 176 | 0.040 |
Why?
| | Drug-Eluting Stents | 1 | 2020 | 101 | 0.040 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 39 | 0.040 |
Why?
| | Aspirin | 1 | 2020 | 122 | 0.040 |
Why?
| | Inpatients | 1 | 2020 | 203 | 0.040 |
Why?
| | Mass Screening | 1 | 2021 | 354 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 150 | 0.040 |
Why?
| | Physicians | 1 | 2021 | 237 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 580 | 0.030 |
Why?
| | Thrombosis | 1 | 2021 | 250 | 0.030 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2020 | 211 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 930 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 721 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 1096 | 0.030 |
Why?
| | Length of Stay | 1 | 2020 | 673 | 0.030 |
Why?
| | Obesity | 1 | 2023 | 1176 | 0.030 |
Why?
| | Adolescent | 1 | 2018 | 6713 | 0.020 |
Why?
|
|
Sawalha's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|